VELA AI
Medspa Public Marketing Risk Review
Vela AI helps medspas review public-facing GLP-1, injectable, before-and-after, review-reply, and AI-generated marketing for common regulatory and patient-privacy risk patterns before publication.
Public content only. Not legal advice.
Also Building: Vela Compliance Binder for MedspasThe $297 Marketing Risk Review is the first front-end offer. The larger product direction is Vela Compliance Binder: a documentation and evidence system for medspa owners and managers.Vela Compliance Binder is designed to help track staff licenses, certifications, SOPs, consent documents, training records, device documentation, expiration dates, checklists, manager approvals, and evidence binder readiness in one place.
What the Compliance Binder TracksStaff licenses and certifications
SOPs and internal policies
Consent forms and treatment templates
Training acknowledgments
Device documentation and maintenance records
Expiration dates and renewal reminders
Daily, weekly, and monthly checklists
Manager approvals and audit trail
Evidence binder export for internal review
Safe ScopeVela AI does not provide legal advice, medical advice, or regulatory guarantees. The system helps organize documents, flag possible issues, and support internal review. Final decisions should be reviewed by the business owner, manager, qualified professional, or legal/compliance advisor when needed.
WHAT WE SCAN
HIGH-RISK MEDSPA CONTENT
Instagram captions, TikTok scripts, website pages, GLP-1 and semaglutide claims, Botox and filler promotions, before-and-after captions, patient testimonials, Google review replies, and AI-generated staff content.
THE OFFER
$297 MARKETING RISK REVIEW
We review selected public marketing and patient-facing language, then provide a risk score, flagged issues, safer rewritten copy, and a 30-minute walkthrough. Findings are informational and intended to support your clinic’s internal compliance review.
CLEAR DELIVERABLES
We give you a risk score, specific flagged issues, detailed explanations for why those issues are risky, safer rewritten copy, a downloadable report, and an option for ongoing monthly monitoring. You receive clear review items and suggested revisions for your team to evaluate before publication.
WHY THIS MATTERS
MARCH 3, 2026 — FDA WARNED 30 COMPANIES OVER COMPOUNDED GLP-1 WEBSITE CLAIMS
The FDA announced 30 warning letters to telehealth companies for false or misleading claims about compounded GLP-1 products offered on their websites. For clinics publishing GLP-1, injectable, before-and-after, review-reply, or AI-generated marketing content, wording and qualification matter. Vela AI provides AI-assisted screening of public marketing copy to support your internal review before publication.
CONTACT US
EMAIL - [email protected]
READY TO REVIEW YOUR MARKETING RISK
Email us to schedule your $297 marketing risk review or ask about ongoing monitoring. We respond within one business day.
Important: Vela AI is not a law firm and does not provide legal advice. It provides AI-assisted compliance risk screening and workflow support. Final review should be performed by clinic leadership, compliance staff, or qualified counsel.
© 2026 Vela AI · Contact [email protected]